ES2261871T3 - Procedimiento para preparar compuestos utiles como intermediarios. - Google Patents
Procedimiento para preparar compuestos utiles como intermediarios.Info
- Publication number
- ES2261871T3 ES2261871T3 ES03077245T ES03077245T ES2261871T3 ES 2261871 T3 ES2261871 T3 ES 2261871T3 ES 03077245 T ES03077245 T ES 03077245T ES 03077245 T ES03077245 T ES 03077245T ES 2261871 T3 ES2261871 T3 ES 2261871T3
- Authority
- ES
- Spain
- Prior art keywords
- procedure
- palladium
- formula
- catalyst
- triphenylphosphine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 title claims abstract description 18
- 150000001875 compounds Chemical class 0.000 title claims abstract description 10
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 10
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 6
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 6
- 150000002367 halogens Chemical class 0.000 claims abstract description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 5
- 239000001257 hydrogen Substances 0.000 claims abstract description 5
- 125000001424 substituent group Chemical group 0.000 claims abstract description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims abstract description 4
- 125000002524 organometallic group Chemical group 0.000 claims abstract description 4
- 239000007858 starting material Substances 0.000 claims abstract description 4
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 claims abstract description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims abstract description 3
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims abstract description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims abstract description 3
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical group [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 claims abstract description 3
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims abstract description 3
- 229910052794 bromium Inorganic materials 0.000 claims abstract description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 3
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims abstract description 3
- 229910052744 lithium Inorganic materials 0.000 claims abstract description 3
- 239000011777 magnesium Substances 0.000 claims abstract description 3
- 229910052749 magnesium Inorganic materials 0.000 claims abstract description 3
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 claims abstract description 3
- 239000003054 catalyst Substances 0.000 claims description 11
- 239000002904 solvent Substances 0.000 claims description 8
- 238000005917 acylation reaction Methods 0.000 claims description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical group [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 4
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 claims description 4
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 claims description 4
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 claims description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 claims description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 229910052763 palladium Inorganic materials 0.000 claims description 3
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 claims description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 2
- 125000004429 atom Chemical group 0.000 claims description 2
- QGJOPFRUJISHPQ-NJFSPNSNSA-N carbon disulfide-14c Chemical compound S=[14C]=S QGJOPFRUJISHPQ-NJFSPNSNSA-N 0.000 claims description 2
- AVPBPSOSZLWRDN-UHFFFAOYSA-M chloropalladium(1+);methanidylbenzene;triphenylphosphane Chemical compound [Pd+]Cl.[CH2-]C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 AVPBPSOSZLWRDN-UHFFFAOYSA-M 0.000 claims description 2
- -1 cyclobenzene Chemical compound 0.000 claims description 2
- VOKXPKSMYJLAIW-UHFFFAOYSA-N nickel;phosphane Chemical group P.[Ni] VOKXPKSMYJLAIW-UHFFFAOYSA-N 0.000 claims description 2
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 claims description 2
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 claims description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 2
- 239000008096 xylene Substances 0.000 claims description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims 1
- HJPOKQICBCJGHE-UHFFFAOYSA-J [C+4].[Cl-].[Cl-].[Cl-].[Cl-] Chemical compound [C+4].[Cl-].[Cl-].[Cl-].[Cl-] HJPOKQICBCJGHE-UHFFFAOYSA-J 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 12
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 229960000351 terfenadine Drugs 0.000 description 5
- 230000010933 acylation Effects 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 150000003053 piperidines Chemical class 0.000 description 4
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 3
- 238000005727 Friedel-Crafts reaction Methods 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 230000001387 anti-histamine Effects 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical group C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 2
- 229960003592 fexofenadine Drugs 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- KVQJVAOMYWTLEO-UHFFFAOYSA-N 2-chlorobutanoyl chloride Chemical compound CCC(Cl)C(Cl)=O KVQJVAOMYWTLEO-UHFFFAOYSA-N 0.000 description 1
- YYEROYLAYAVZNW-UHFFFAOYSA-N 2-methyl-2-phenylpropanoic acid Chemical compound OC(=O)C(C)(C)C1=CC=CC=C1 YYEROYLAYAVZNW-UHFFFAOYSA-N 0.000 description 1
- CDIIZULDSLKBKV-UHFFFAOYSA-N 4-chlorobutanoyl chloride Chemical compound ClCCCC(Cl)=O CDIIZULDSLKBKV-UHFFFAOYSA-N 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001466 anti-adreneric effect Effects 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 230000001705 anti-serotonergic effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 238000007080 aromatic substitution reaction Methods 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000006880 cross-coupling reaction Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000007345 electrophilic aromatic substitution reaction Methods 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000003485 histamine H2 receptor antagonist Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- ZEUXAIYYDDCIRX-UHFFFAOYSA-N losartan carboxylic acid Chemical compound CCCCC1=NC(Cl)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C2=NNN=N2)C=C1 ZEUXAIYYDDCIRX-UHFFFAOYSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/76—Unsaturated compounds containing keto groups
- C07C59/86—Unsaturated compounds containing keto groups containing six-membered aromatic rings and other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
- C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
- C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Un procedimiento para preparar un regioisómero substancialmente puro de fórmula: en la que R3¿ es -COOH, -COOR4, -CON(R4)2, -COSR4; R4 es un alquilo con 1 a 6 átomos de carbono; A son los sustituyentes de su anillo, cada uno de los cuales puede ser diferente o el mismo y se seleccionan del grupo que consiste en hidrógeno, halógenos, alquilo, hidroxilo o alcoxi; dicho procedimiento comprende acilar un compuesto de partida de fórmula: en la que X1 es un halógeno, trialquilo de estaño, borato de dialquilo, triflato o reactivos organometálicos de litio o magnesio derivados de bromo o yodo, con cualesquiera grupos alquilo que tengan de 1 a 4 átomos de carbono y siendo lineales o ramificados; R3¿ es -COOH, -COOR4, -CON(R4)2, -COSR4; con un compuesto de fórmula: bajo condiciones eficaces para producir el regioisómero substancialmente puro.
Description
Procedimiento para preparar compuestos útiles
como intermediarios.
El presente invento se refiere a un
procedimiento para preparar regioisómeros substancialmente puros
útiles como intermediarios en la preparación de derivados de
piperidina.
Terfenadina,
1-(p-tert-butilfenil)-4-[4'-(\alpha-hidroxidifenilmetil)-1'-piperidinil]-butanol,
es un antihistamínico no sedante. Se ha descrito como un antagonista
específico del receptor H_{2}, que está también exento de
cualquier efecto anticolinérgico, antiserotoninérgico y
antiadrenérgico, tanto in vitro como in vivo. Véase D.
McTavish, K.L. Goa, M. Ferrill, Drugs, 1990, 39, 552; C.R.
Kingsolving, N.L. Mónroe, A.A. Carr, Pharmacologist, 1973, 15, 221;
J.K.
Woodward, N.L. Munro, Arzne-im-Forsch, 1982, 32, 1154; K.V. Mann, K.J. Tietze, Clin. Pharm. 1989, 6, 331. Se ha hecho un gran esfuerzo en la investigación de las relaciones estructura-actividad de análogos de terfenadina y esto se refleja en el gran número de patentes de EE.UU. que describen este compuesto y estructuras relacionadas según
sigue:
Woodward, N.L. Munro, Arzne-im-Forsch, 1982, 32, 1154; K.V. Mann, K.J. Tietze, Clin. Pharm. 1989, 6, 331. Se ha hecho un gran esfuerzo en la investigación de las relaciones estructura-actividad de análogos de terfenadina y esto se refleja en el gran número de patentes de EE.UU. que describen este compuesto y estructuras relacionadas según
sigue:
\vskip1.000000\baselineskip
- Patente de EE.UU. nº 3.687.956 de Zivkovic
- Patente de EE.UU. nº 3.806.526 de Carr, et al.
- Patente de EE.UU. nº 3.829.433 de Carr, et al.
- Patente de EE.UU. nº 3.862.173 de Carr, et al.
- Patente de EE.UU. nº 3.878.217 de Carr, et al.
- Patente de EE.UU. nº 3.922.276 de Duncan, et al.
- Patente de EE.UU. nº 3.931.297 de Carr, et al.
- Patente de EE.UU. nº 3.941.795 de Carr, et al.
- Patente de EE.UU. nº 3.946.022 de Carr, et al.
- Patente de EE.UU. nº 3.956.296 de Duncan, et al.
- Patente de EE.UU. nº 3.965.257 de Carr, et al.
- Patente de EE.UU. nº 4.742.175 de Fawcett, et al.
\vskip1.000000\baselineskip
Terfenadina se ha asociado con arritmias
anormales potencialmente fatales en algunos pacientes con enfermedad
hepática o que también toman el fármaco antifúngico ketoconazol o el
antibiótico eritromicina. En estudios metabólicos animales y
humanos, terfenadina ha mostrado experimentar un elevado efecto
inicial de paso, lo que da como resultado concentraciones
plasmáticas fácilmente medibles del metabolito principal, el ácido
4-[4-[4-hidroxidifenilmetil)-1-piperidinil]-1-hidroxibutil]-\alpha,\alpha-dimetilfenilacético,
también conocido como metabolito ácido terfenadina carboxilato. El
metabolito ácido carboxílico de la terfenadina también posee
actividad antihistamínica en modelos animales y puede carecer de los
efectos secundarios cardiacos observados con terfenadina.
Los derivados de piperidina referidos al
metabolito ácido terfenadina carboxilato se describen en las
siguientes patentes de EE.UU.:
\vskip1.000000\baselineskip
- Patente de EE.UU. nº 4.254.129 de Carr, et al.
- Patente de EE.UU. nº 4.254.130 de Carr, et al.
- Patente de EE.UU. nº 4.285.957 de Carr, et al.
- Patente de EE.UU. nº 4.285.958 de Carr, et al.
\newpage
En estas patentes, el ácido
4-[4-[4-hidroxidifenilmetil)-1-piperidinil]-1-hidroxibutil]-\alpha,\alpha-dimetilbencenoacético
y sus compuestos relacionados se preparan por alquilación de un
derivado de piperidina sustituido de fórmula:
con una fenilcetona sustituida con
\omega-haloalquilo de
fórmula:
en la que los sustituyentes halo,
R_{1}, R_{2}, n, z y R_{6} se describen en la columna 6 de la
patente de EE.UU. nº
4.254.130.
Además se describe que la fenilcetona sustituida
con \omega-haloalquilo en la que Z es hidrógeno se
prepara por reacción de un éster alquílico inferior
C_{1-6} lineal o ramificado apropiado del ácido
\alpha,\alpha-dimetilfenilacético con el
compuesto de la siguiente fórmula:
bajo las condiciones generales de
una acilación de Friedel-Crafts, en la que halo y m
se describen en la columna 11 de la patente de EE.UU. nº 4.254.129.
La reacción se lleva a cabo en disulfuro de carbono como el
disolvente
preferido.
El solicitante ha descubierto que la preparación
de
4-(4-cloro-1-oxobutil)-\alpha,\alpha-dimetilfenilacetato
de etilo por reacción de cloruro de 4-clorobutirilo,
cloruro de aluminio y
\alpha,\alpha-dimetilfenilacetato de etilo en
disulfuro de carbono, según se describe en el Ejemplo 1 de las
patentes de EE.UU. nº 4.254.130 y 4.285.958 proporciona una mezcla
inseparable de regioisómeros aromáticos monosustituidos de
fórmula:
en la que el sustituyente
clorobutirilo se une a uno de los tres carbonos aromáticos que se
encuentran meta o para respecto al sustituyente dimetilacetato.
Estos regioisómeros no son separables por técnicas estándares de
cromatografía de capa fina o cromatografía de columna y la
espectroscopía de resonancia magnética nuclear de protón de bajo
campo no es concluyente en la identificación del producto de esta
reacción como una mezcla. Cuando la mezcla de regioisómeros
aromáticos monosustituidos de la fórmula precedente reacciona con
una piperidina de
fórmula:
se obtiene una segunda mezcla de
regioisómeros aromáticos de
fórmula:
en la que se obtiene una mezcla de
regioisómeros meta y para
monosustituidos.
Es conocido en la técnica que un sustituyente
monoalquilo en un anillo benceno es orto, orientándose a para en
reacciones de sustitución aromática electrófilas, tales como una
reacción de Friedel-Crafts. Por tanto, podría
esperarse que la reacción de Friedel-Crafts del
cloruro de \alpha-clorobutirilo con
\alpha,\alpha-dimetilfenilacetato de etilo
rindiese, predominantemente, el producto sustituido en para de
fórmula:
debido al donador de electrones,
marca orientadora hacia para del sustituyente dimetilalquilo
combinado con el impedimento estérico asociado con la reacción de
las posiciones orto. En la práctica, el efecto inductivo electrónico
de retirada del éster carboxílico de
\alpha,\alpha-dimetilfenilacetato de etilo
contrarresta el esperado efecto donador de electrones alquilo, lo
que da como resultado un efecto de dirección no significativo para
la reacción de sustitución aromática. Para la reacción descrita, da
como resultado una mezcla estadística de regioisómeros de meta a
para, en la que predominan las dos posiciones
meta.
La segunda mezcla de regioisómeros anterior
puede convertirse en una tercera mezcla de regioisómeros de
fórmula:
Aunque la segunda mezcla de regioisómeros y la
tercera mezcla de regioisómeros pueden analizarse mediante
experimentos de HPLC, no se ha llevado a cabo una separación
práctica de regioisómeros substancialmente puros para obtener
cantidades de gramos. Cada mezcla (incluida la primera), se espera
que contenga 33% del isómero para y 67% del isómero meta. Dado que
estos componentes son inseparables, no se ha podido obtener uno
cualquiera de los regioisómeros en cada mezcla en forma
substancialmente pura.
El presente invento se refiere a un
procedimiento para preparar un regioisómero substancialmente puro de
fórmula:
en la
que
R_{3'} es -COOH, -COOR_{4},
-CON(R_{4})_{2}, -COSR_{4};
R_{4} es un alquilo con 1 a 6 átomos de
carbono;
A son los sustituyentes de su anillo, cada uno
de los cuales puede ser diferente o el mismo y se seleccionan del
grupo que consiste en hidrógeno, halógenos, alquilo, hidroxilo o
alcoxi;
dicho procedimiento comprende acilar un
compuesto de partida de fórmula:
\vskip1.000000\baselineskip
en la
que
X_{1} es un halógeno, trialquilo de estaño,
borato de dialquilo, triflato o reactivos organometálicos de litio o
magnesio derivados de bromo o yodo, con cualesquiera grupos alquilo
que tengan de 1 a 4 átomos de carbono y siendo lineales o
ramificados;
R_{3'} es -COOH, -COOR_{4},
-CON(R_{4})_{2}, -COSR_{4};
con un compuesto de fórmula:
bajo condiciones eficaces para
producir el regioisómero substancialmente
puro.
En el procedimiento del presente invento el
regioisómero substancialmente puro se produce por acilación de un
compuesto de partida de fórmula:
\newpage
con un compuesto de
fórmula:
Esta reacción de acilación se lleva a cabo en un
disolvente apropiado en presencia de un catalizador apropiado
durante aproximadamente 1 a 120 horas y a temperaturas de
aproximadamente 0ºC a la temperatura de reflujo del disolvente. Los
disolventes adecuados para la acilación incluyen: disolventes
hidrocarbonados, tales como benceno, tolueno, xileno o cilohexano;
hidrocarburos halogenados, tales como clorobenceno, dicloroetano,
cloruro de metileno, cloroformo o tetracloruro de carbono; disulfuro
de carbono; dimetilformamida; disolventes volátiles, como
tetrahidrofurano y dieteliéter; o dioxano.
Puede emplearse un gran número de catalizadores
cuando A es hidrógeno. Catalizadores adecuados incluyen
catalizadores de paladio, como cloruro de paladio, acetato de
paladio, tetrakis(trifenilfosfina)paladio(0),
diclorobis(trifenilfosfina)paladio(II) o
bencilclorobis(trifenilfosfina)paladio(II); o
catalizadores de níquel-fosfina. La acilación
también puede llevarse a cabo en presencia de cloruro de litio o
trifenilfosifina añadidos. Esta última reacción de acilación se
conoce en la técnica como reacciones de acoplamiento cruzado de
organometálico y son guiadas por los procedimientos generales de D.
Milstein, et al., J Org Chem, 1979, 44, 1613; J.W.
Labadie, et al., J Org Chem, 1983, 48, 4634; C.
Sahlberg, et al., Tetrahedron Letters, 1983, 24, 5137:
D. Milstein, et al., J Am Chem Soc, 1978, 100, 3636 y
K. Tamao, et al., Tetrahedron, 1982, 38, 3347.
Una vez se produce el regiosiómero
substancialmente puro del presente invento por el procedimiento
anterior, hay numerosos procedimientos para utilizar ese compuesto
para producir los derivados de piperidina del presente invento.
Claims (7)
-
\global\parskip0.960000\baselineskip
1. Un procedimiento para preparar un regioisómero substancialmente puro de fórmula:14 en la queR_{3'} es -COOH, -COOR_{4}, -CON(R_{4})_{2}, -COSR_{4};R_{4} es un alquilo con 1 a 6 átomos de carbono;A son los sustituyentes de su anillo, cada uno de los cuales puede ser diferente o el mismo y se seleccionan del grupo que consiste en hidrógeno, halógenos, alquilo, hidroxilo o alcoxi;dicho procedimiento comprende acilar un compuesto de partida de fórmula:15 en la queX_{1} es un halógeno, trialquilo de estaño, borato de dialquilo, triflato o reactivos organometálicos de litio o magnesio derivados de bromo o yodo, con cualesquiera grupos alquilo que tengan de 1 a 4 átomos de carbono y siendo lineales o ramificados;R_{3'} es -COOH, -COOR_{4}, -CON(R_{4})_{2}, -COSR_{4};con un compuesto de fórmula:16 bajo condiciones eficaces para producir el regioisómero substancialmente puro. - 2. Un procedimiento, de acuerdo con la reivindicación 1, en el que la reacción de acilación se lleva a cabo en un disolvente y en presencia de un catalizador.
- 3. Un procedimiento, como se reivindica en la reivindicación 2, en el que el disolvente se selecciona del grupo que comprende benceno, tolueno, xileno, ciclohexano, ciclobenceno, dicloroetano, cloruro de metileno, cloroformo, tetracloruro de carbono, disulfuro de carbono, dimetilformamida, tetrahidrofurano, dietiléter y dioxano.
- 4. Un procedimiento, de acuerdo con la reivindicación 2 o reivindicación 3, en el que el catalizador es un catalizador de paladio.
- 5. Un procedimiento, de acuerdo con la reivindicación 4, en el que el catalizador de paladio se selecciona del grupo que comprende cloruro de paladio, acetato de paladio, tetrakis(trifenilfosfina)paladio(0), diclorobis(trifenilfosfina)paladio(II), bencilclorobis(trifenilfosfina)paladio(II).
- 6. Un procedimiento, de acuerdo con la reivindicación 2 o reivindicación 3, en el que el catalizador es un catalizador de níquel-fosfina.
- 7. Un procedimiento, de acuerdo con una cualquiera de las reivindicaciones 4 a 6, que se lleva a cabo en presencia de cloruro de litio o trifenilfosfina.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8310293A | 1993-06-24 | 1993-06-24 | |
US83102 | 1993-06-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2261871T3 true ES2261871T3 (es) | 2006-11-16 |
Family
ID=22176189
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES94920762T Expired - Lifetime ES2129130T3 (es) | 1993-06-24 | 1994-06-21 | Derivados de piperidina y proceso para su produccion. |
ES00200419T Expired - Lifetime ES2211444T3 (es) | 1993-06-24 | 1994-06-21 | Compuestos utiles como productos intermedios en la produccion de derivados de piperidina. |
ES03077245T Expired - Lifetime ES2261871T3 (es) | 1993-06-24 | 1994-06-21 | Procedimiento para preparar compuestos utiles como intermediarios. |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES94920762T Expired - Lifetime ES2129130T3 (es) | 1993-06-24 | 1994-06-21 | Derivados de piperidina y proceso para su produccion. |
ES00200419T Expired - Lifetime ES2211444T3 (es) | 1993-06-24 | 1994-06-21 | Compuestos utiles como productos intermedios en la produccion de derivados de piperidina. |
Country Status (16)
Country | Link |
---|---|
US (9) | US5750703A (es) |
EP (4) | EP0703902B1 (es) |
JP (4) | JP3034047B2 (es) |
KR (2) | KR100387348B1 (es) |
AT (3) | ATE322473T1 (es) |
AU (1) | AU670004B2 (es) |
CA (1) | CA2147126C (es) |
DE (3) | DE69434696T2 (es) |
DK (3) | DK1369409T3 (es) |
ES (3) | ES2129130T3 (es) |
FI (1) | FI109691B (es) |
HU (1) | HU226559B1 (es) |
NO (2) | NO308599B1 (es) |
NZ (1) | NZ268513A (es) |
PT (2) | PT1369409E (es) |
WO (1) | WO1995000482A1 (es) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RO116043B1 (ro) * | 1992-08-03 | 2000-10-30 | Sepracor Inc | Compozitie farmaceutica |
EP0703902B1 (en) | 1993-06-24 | 1998-12-16 | Albany Molecular Research, Inc. | Process for the production of piperidine derivatives |
US20020007068A1 (en) | 1999-07-16 | 2002-01-17 | D'ambra Thomas E. | Piperidine derivatives and process for their production |
JP3712208B2 (ja) | 1993-06-25 | 2005-11-02 | メレルファーマスーティカルズ インコーポレイテッド | 抗ヒスタミン性の4−ジフェニルメチル/ジフェニルメトキシピペリジン誘導体類を製造する新規な中間体 |
US20030045722A1 (en) * | 1994-05-18 | 2003-03-06 | Henton Daniel R. | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
ES2176329T3 (es) * | 1994-05-18 | 2002-12-01 | Aventis Pharma Inc | Procedimientos para preparar formas anhidras e hidratadas de derivados antihistaminicos de piperidina, sus polimeros y pseudomorfos. |
DK0812195T3 (da) | 1995-02-28 | 2003-03-03 | Aventis Pharma Inc | Farmaceutisk sammensætning til piperidinoalkanolforbindelser |
US6201124B1 (en) | 1995-12-21 | 2001-03-13 | Albany Molecular Research, Inc. | Process for production of piperidine derivatives |
US6153754A (en) | 1995-12-21 | 2000-11-28 | Albany Molecular Research, Inc. | Process for production of piperidine derivatives |
US5925761A (en) * | 1997-02-04 | 1999-07-20 | Sepracor Inc. | Synthesis of terfenadine and derivatives |
ZA985939B (en) | 1997-07-08 | 2000-01-10 | Aristocrat Leisure Ind Pty Ltd | Slot machine game and system with improved jackpot feature. |
NZ501248A (en) * | 1997-08-26 | 2001-06-29 | Aventis Pharma Inc | Pharmaceutical composition for combination of piperidinoalkanol-decongestant |
US6194431B1 (en) * | 1998-04-14 | 2001-02-27 | Paul D. Rubin | Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors |
NZ528839A (en) * | 1998-07-02 | 2005-03-24 | Aventis Pharma Inc | Antihistaminic piperidine derivatives and intermediates |
US6700012B2 (en) | 1998-07-02 | 2004-03-02 | Aventis Pharmaceuticals Inc. | Antihistaminic piperidine derivatives and intermediates for the preparation thereof |
AU2007200674C1 (en) * | 1998-07-02 | 2011-02-24 | Aventisub Llc | Novel antihistaminic piperidine derivatives and intermediates for the preparation thereof |
US6683094B2 (en) | 1998-07-02 | 2004-01-27 | Aventis Pharmaceuticals Inc. | Antihistaminic piperidine derivatives and intermediates for the preparation thereof |
US6362375B1 (en) | 1999-12-03 | 2002-03-26 | College Of The Holy Cross | Process for the preparation of aryl ketones generating reduced amounts of toxic byproducts |
US6613906B1 (en) | 2000-06-06 | 2003-09-02 | Geneva Pharmaceuticals, Inc. | Crystal modification |
GB0018691D0 (en) * | 2000-07-28 | 2000-09-20 | Rolabo Sl | Process |
US6613907B2 (en) | 2000-11-08 | 2003-09-02 | Amr Technology, Inc. | Process for the production of piperidine derivatives with microorganisms |
IL158334A0 (en) * | 2001-04-09 | 2004-05-12 | Teva Pharma | Polymorphs of fexofenadine hydrochloride |
US20030021849A1 (en) * | 2001-04-09 | 2003-01-30 | Ben-Zion Dolitzky | Polymorphs of fexofenadine hydrochloride |
US6743941B2 (en) * | 2001-06-15 | 2004-06-01 | Aventis Pharma Deutschland Gmbh | Process for the production of piperidine derivatives |
WO2003000658A1 (en) * | 2001-06-25 | 2003-01-03 | Aurobindo Pharma Limited | PROCESS FOR THE PREPARATION OF A HIGHLY PURE PHARMACEUTICAL INTERMEDIATE, 4-(CYCLOPROPYLCARBONYL)-α,α-DIMETHYLPHENYLACETIC ACID |
US6593499B2 (en) * | 2001-08-29 | 2003-07-15 | Council Of Scientific & Industrial Research | Process for the preparation of phenyl ketones |
EP1453509A2 (en) * | 2001-11-08 | 2004-09-08 | Teva Pharmaceutical Industries Ltd. | Polymorphs of fexofenadine base |
IL163666A0 (en) | 2002-02-22 | 2005-12-18 | New River Pharmaceuticals Inc | Active agent delivery systems and methods for protecting and administering active agents |
US20040044038A1 (en) * | 2002-06-10 | 2004-03-04 | Barnaba Krochmal | Polymorphic form XVI of fexofenadine hydrochloride |
US20050026890A1 (en) * | 2003-07-31 | 2005-02-03 | Robinson Cynthia B. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an antihistamine for treatment of asthma or chronic obstructive pulmonary disease |
US20050065183A1 (en) * | 2003-07-31 | 2005-03-24 | Indranil Nandi | Fexofenadine composition and process for preparing |
GB0319935D0 (en) | 2003-08-26 | 2003-09-24 | Cipla Ltd | Polymorphs |
TW200517114A (en) | 2003-10-15 | 2005-06-01 | Combinatorx Inc | Methods and reagents for the treatment of immunoinflammatory disorders |
KR20070007196A (ko) * | 2004-04-26 | 2007-01-12 | 테바 파마슈티컬 인더스트리즈 리미티드 | 펙소페나딘 히드로클로라이드의 결정형 및 이의 제조 방법 |
ITMI20041568A1 (it) * | 2004-07-30 | 2004-10-30 | Dipharma Spa | "polimorfi di fexofenadina base" |
US7498345B2 (en) | 2004-09-17 | 2009-03-03 | Albany Molecular Research, Inc. | Process for production of piperidine derivatives |
US7498443B2 (en) * | 2004-09-17 | 2009-03-03 | Albany Molecular Research, Inc. | Process for production of carebastine |
JP2008514641A (ja) * | 2004-09-28 | 2008-05-08 | テバ ファーマシューティカル インダストリーズ リミティド | 結晶形フェキソフェナジン、およびその調製方法 |
US7841939B2 (en) | 2005-09-09 | 2010-11-30 | Igt | Server based gaming system having multiple progressive awards |
JP2009514969A (ja) | 2005-11-09 | 2009-04-09 | コンビナトアールエックス インコーポレーティッド | 医学的状態を治療するための方法、組成物、およびキット |
US7780520B2 (en) | 2006-03-15 | 2010-08-24 | Igt | Gaming device having multiple different types of progressive awards |
WO2007135693A2 (en) * | 2006-05-18 | 2007-11-29 | Ind-Swift Laboratories Limited | Intermediates useful for the preparation of antihistaminic piperidine derivative |
ITMI20061492A1 (it) * | 2006-07-27 | 2008-01-28 | Archimica Srl | Processo per la preparazione di fexofenadina. |
US8070597B2 (en) | 2006-08-03 | 2011-12-06 | Igt | Gaming device and method having multiple progressive award levels and a secondary game for advancing through the progressive award levels |
US9047733B2 (en) | 2006-11-08 | 2015-06-02 | Igt | Gaming system and method for providing multiple level progressive awards with increased odds of winning higher level progressive awards |
US20090306135A1 (en) | 2008-03-24 | 2009-12-10 | Mukesh Kumar Sharma | Stable amorphous fexofenadine hydrochloride |
WO2009136412A2 (en) * | 2008-04-25 | 2009-11-12 | Matrix Laboratories Limited | PROCESS FOR PREPARATION OF 4-[4-(4-(HYDROXYDIPHENYLMETHYL)- 1-PIPERIDINYL]-1-OXOBUTYL]-α,α-DIMETHYLBENZENE ACETIC ACID METHYL ESTER AND USE THEREOF |
EP3067352A3 (en) * | 2008-05-07 | 2016-10-19 | Cardioxyl Pharmaceuticals Inc. | Novel nitroso compounds as nitroxyl donors and methods of use thereof |
KR20110017365A (ko) * | 2008-05-30 | 2011-02-21 | 페어필드 클리니컬 트라이얼즈 엘엘씨 | 피부 염증 및 변색을 위한 방법 및 조성물 |
WO2010021681A2 (en) * | 2008-08-18 | 2010-02-25 | Combinatorx (Singapore) Pte. Ltd. | Compositions and methods for treatment of viral diseases |
EP2289867A3 (en) | 2009-08-19 | 2012-04-25 | Jubilant Organosys Limited | A process for producing 4-(4-halo-1-oxybutyl)-alpha,alpha-dimethylbenzene acetic acid or alkyl esters thereof |
US20110130711A1 (en) * | 2009-11-19 | 2011-06-02 | Follica, Inc. | Hair growth treatment |
CN102070512B (zh) * | 2009-11-21 | 2014-11-19 | 浙江华海药业股份有限公司 | 一种高纯度非索非那定及其中间体的合成路线与制备方法 |
WO2011063339A1 (en) * | 2009-11-23 | 2011-05-26 | Cardioxyl Pharmaceuticals, Inc. | Nitroxyl donors for the treatment of pulmonary hypertension |
CN102962288A (zh) * | 2012-11-21 | 2013-03-13 | 苏州江南航天机电工业有限公司 | 圆弧状大板与直板拼接工艺 |
ITMI20131652A1 (it) | 2013-10-07 | 2015-04-08 | Dipharma Francis Srl | Procedimento per la purificazione di derivati dell'acido 2-fenil-2-metil-propanoico |
HUE047669T2 (hu) | 2015-10-22 | 2020-05-28 | Sanofi Aventis Deutschland | Eljárás fexofenadin és az eljárásban használt köztitermékek elõállítására |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4028404A (en) * | 1967-07-31 | 1977-06-07 | Allen & Hanburys Limited | Acetic acid derivatives |
GB1242169A (en) * | 1969-04-09 | 1971-08-11 | Ucb Sa | Piperidine derivatives |
US3839431A (en) * | 1970-07-13 | 1974-10-01 | Squibb & Sons Inc | Cyclopropylmethylphenylacetic acids and derivatives |
US3898271A (en) * | 1971-06-08 | 1975-08-05 | Squibb & Sons Inc | Cyclopropylmethylphenylacetic acids and derivatives |
BE794596A (fr) * | 1972-01-28 | 1973-05-16 | Richardson Merrell Inc | Piperidinoalcanone-oximes substituees et leur procede de preparation |
US3965257A (en) * | 1972-01-28 | 1976-06-22 | Richardson-Merrell Inc. | Compositions and methods for the treatment of the symptoms of histamine induced allergic reactions |
US3806526A (en) * | 1972-01-28 | 1974-04-23 | Richardson Merrell Inc | 1-aroylalkyl-4-diphenylmethyl piperidines |
BE794598A (fr) * | 1972-01-28 | 1973-05-16 | Richardson Merrell Inc | Nouveaux derives olefiniques de piperidines substituees en 4 et leur procede de preparation |
US3878217A (en) * | 1972-01-28 | 1975-04-15 | Richardson Merrell Inc | Alpha-aryl-4-substituted piperidinoalkanol derivatives |
US3941795A (en) * | 1974-02-08 | 1976-03-02 | Richardson-Merrell Inc. | α-ARYL-4-SUBSTITUTED PIPERIDINOALKANOL DERIVATIVES |
US3931197A (en) * | 1974-02-08 | 1976-01-06 | Richardson-Merrell Inc. | Substituted piperidine derivatives |
US3946022A (en) * | 1974-03-04 | 1976-03-23 | Richardson-Merrell Inc. | Piperidine derivatives |
US3922276A (en) * | 1974-12-11 | 1975-11-25 | Robins Co Inc A H | 1-Substituted-4-benzylidenepiperidines |
US3956296A (en) * | 1974-12-11 | 1976-05-11 | A. H. Robins Company, Incorporated | 1-Substituted-4-benzylpiperidines |
DD141422A5 (de) * | 1978-01-27 | 1980-04-30 | Schering Ag | Verfahren zur herstellung von phenylessigsaeure-derivaten |
US4254130A (en) * | 1979-04-10 | 1981-03-03 | Richardson-Merrell Inc. | Piperidine derivatives |
US4285958A (en) * | 1979-04-10 | 1981-08-25 | Richardson-Merrell Inc. | 1-Piperidine-alkylene ketones, pharmaceutical compositions thereof and method of use thereof |
US4254129A (en) * | 1979-04-10 | 1981-03-03 | Richardson-Merrell Inc. | Piperidine derivatives |
US4285957A (en) * | 1979-04-10 | 1981-08-25 | Richardson-Merrell Inc. | 1-Piperidine-alkanol derivatives, pharmaceutical compositions thereof, and method of use thereof |
GB8321157D0 (en) * | 1983-08-05 | 1983-09-07 | Fordonal Sa | Piperidine derivatives |
IT1200123B (it) | 1985-09-27 | 1989-01-05 | Ind Chimica Srl | Procedimento per la preparazione di alfa-(p-terbutilfenil)-4-(idrossidifenilmetil)-1-piperidinobutanolo |
US4742175A (en) * | 1986-05-07 | 1988-05-03 | Merrell Dow Pharmaceuticals Inc. | Preparation of polymorphically pure terfenadine |
AU671822B2 (en) * | 1992-04-10 | 1996-09-12 | Aventisub Ii Inc. | 4-diphenylmethyl piperidine derivatives and process for their preparation |
RO116043B1 (ro) * | 1992-08-03 | 2000-10-30 | Sepracor Inc | Compozitie farmaceutica |
US20020007068A1 (en) * | 1999-07-16 | 2002-01-17 | D'ambra Thomas E. | Piperidine derivatives and process for their production |
EP0703902B1 (en) * | 1993-06-24 | 1998-12-16 | Albany Molecular Research, Inc. | Process for the production of piperidine derivatives |
JP3712208B2 (ja) * | 1993-06-25 | 2005-11-02 | メレルファーマスーティカルズ インコーポレイテッド | 抗ヒスタミン性の4−ジフェニルメチル/ジフェニルメトキシピペリジン誘導体類を製造する新規な中間体 |
US6147216A (en) | 1993-06-25 | 2000-11-14 | Merrell Pharmaceuticals Inc. | Intermediates useful for the preparation of antihistaminic piperidine derivatives |
WO2002028814A2 (en) * | 2000-10-06 | 2002-04-11 | Regents Of The University Of California | Nmda receptor channel blocker with neuroprotective activity |
-
1994
- 1994-06-21 EP EP94920762A patent/EP0703902B1/en not_active Expired - Lifetime
- 1994-06-21 DK DK03077245T patent/DK1369409T3/da active
- 1994-06-21 DE DE69434696T patent/DE69434696T2/de not_active Expired - Lifetime
- 1994-06-21 ES ES94920762T patent/ES2129130T3/es not_active Expired - Lifetime
- 1994-06-21 HU HU9503719A patent/HU226559B1/hu unknown
- 1994-06-21 DK DK00200419T patent/DK1026147T3/da active
- 1994-06-21 DE DE69415319T patent/DE69415319T2/de not_active Expired - Lifetime
- 1994-06-21 CA CA002147126A patent/CA2147126C/en not_active Expired - Lifetime
- 1994-06-21 DE DE69433346T patent/DE69433346T2/de not_active Expired - Lifetime
- 1994-06-21 AT AT03077245T patent/ATE322473T1/de active
- 1994-06-21 EP EP00200419A patent/EP1026147B1/en not_active Expired - Lifetime
- 1994-06-21 ES ES00200419T patent/ES2211444T3/es not_active Expired - Lifetime
- 1994-06-21 AT AT94920762T patent/ATE174589T1/de active
- 1994-06-21 PT PT03077245T patent/PT1369409E/pt unknown
- 1994-06-21 JP JP7502981A patent/JP3034047B2/ja not_active Expired - Lifetime
- 1994-06-21 DK DK94920762T patent/DK0703902T3/da active
- 1994-06-21 KR KR10-2002-7009756A patent/KR100387348B1/ko not_active IP Right Cessation
- 1994-06-21 AT AT00200419T patent/ATE254594T1/de active
- 1994-06-21 KR KR1019950705909A patent/KR100387347B1/ko not_active IP Right Cessation
- 1994-06-21 NZ NZ268513A patent/NZ268513A/en not_active IP Right Cessation
- 1994-06-21 PT PT00200419T patent/PT1026147E/pt unknown
- 1994-06-21 AU AU71748/94A patent/AU670004B2/en not_active Expired
- 1994-06-21 EP EP03077245A patent/EP1369409B1/en not_active Expired - Lifetime
- 1994-06-21 ES ES03077245T patent/ES2261871T3/es not_active Expired - Lifetime
- 1994-06-21 WO PCT/US1994/006873 patent/WO1995000482A1/en active IP Right Grant
- 1994-06-21 EP EP96200338A patent/EP0723958A1/en not_active Ceased
-
1995
- 1995-02-02 US US08/382,649 patent/US5750703A/en not_active Expired - Lifetime
- 1995-02-02 US US08/382,425 patent/US5589487A/en not_active Expired - Lifetime
- 1995-05-31 US US08/456,273 patent/US5578610A/en not_active Expired - Lifetime
- 1995-05-31 US US08/455,991 patent/US5581011A/en not_active Expired - Lifetime
- 1995-12-12 NO NO19955023A patent/NO308599B1/no not_active IP Right Cessation
- 1995-12-27 FI FI956270A patent/FI109691B/fi not_active IP Right Cessation
-
1996
- 1996-08-08 US US08/700,556 patent/US5663412A/en not_active Expired - Lifetime
-
1997
- 1997-12-19 US US08/994,357 patent/US5994549A/en not_active Expired - Lifetime
-
1998
- 1998-09-24 JP JP26960698A patent/JP3195297B2/ja not_active Expired - Lifetime
-
1999
- 1999-09-21 NO NO994582A patent/NO994582D0/no not_active Application Discontinuation
-
2000
- 2000-08-01 JP JP2000233271A patent/JP3658291B2/ja not_active Expired - Lifetime
-
2001
- 2001-11-15 JP JP2001350148A patent/JP4124998B2/ja not_active Expired - Lifetime
-
2005
- 2005-10-14 US US11/250,924 patent/US7238834B2/en not_active Expired - Fee Related
-
2006
- 2006-06-19 US US11/455,531 patent/US7390906B2/en not_active Expired - Fee Related
-
2008
- 2008-05-29 US US12/128,799 patent/US20080227983A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2261871T3 (es) | Procedimiento para preparar compuestos utiles como intermediarios. | |
US6046213A (en) | Neuroprotective 3-(piperidinyl-1)-chroman-4,7-diol and 1-(4-hydroxyphenyl)-2-(piperidinyl-1)-alkanol derivatives | |
JPS6051174A (ja) | 新規アリ−ルピペリジン誘導体の製造方法 | |
US3405134A (en) | Quinuclidyl esters of aromatic acids | |
CA1055041A (en) | Ketone derivatives | |
US6797826B2 (en) | Piperidine derivatives and process for their production | |
JP2725378B2 (ja) | カルバミド酸エステル誘導体 | |
JP2931986B2 (ja) | アラルキルアミン誘導体 | |
Casy et al. | Diastereoisomeric esters of 1, 2-dimethyl-4-phenylpiperidin-4-ol and related compounds | |
US5091429A (en) | Derivatives of 4-amino-1-trifluoromethyltetralines their preparation and their therapeutic application | |
JP2861274B2 (ja) | アミノケトン誘導体 | |
JPH04112868A (ja) | 置換ヘテロ環を有するフェニルカルボン酸誘導体 | |
Lockhart et al. | Analgetics based on the pyrrolidine ring. 7 | |
AU729549B2 (en) | Piperidine derivatives and process for their production | |
US3117976A (en) | Nu-alkyl-pyrrolidine-2-methanol, alpha cyclohexyl mandelates | |
US2250006A (en) | Anesthetic compounds | |
US3487078A (en) | Improvements in or relating to dibenzocycloheptane compounds | |
US2810723A (en) | lysergic acid derivatives acylated at | |
Van Bekkum et al. | Studies on cyclohexane derivatives: I. A chemical proof of the configuration of the two 1, 4‐dimethyl‐cyclohexanes | |
US3123611A (en) | n naoh | |
US3438990A (en) | Novel 1-cycloalkenyl-piperidines | |
US2250005A (en) | Anesthetic compounds | |
US3575988A (en) | Piperidyl bis(parachlorophenoxy) acetates | |
SE178754C1 (es) | ||
CS218028B1 (cs) | Substituované 1- (4-amino-6,7-diinetlioxychinazolin-2-yl)-3,4- -dehydropiperidiny a způsob jejich přípravy |